60 DEGREES PHARMACEUTICALS, INC. Annual Report - How They Did This Year

I’m writing this guide to help you understand how 60 Degrees Pharmaceuticals (SXTP) performed this year. My goal is to turn complex financial filings into plain English so you can decide if this company fits your investment goals.

1. What does this company do?

60 Degrees Pharmaceuticals is a specialty drug company focused on infectious diseases. They are best known for Arakoda, an FDA-approved malaria prevention drug sold since 2019. They are now working to expand into treatments for babesiosis, influenza, and COVID-19. They operate as a "virtual" company, outsourcing manufacturing and clinical trials to keep costs low while they focus on regulatory approval and commercial sales.

2. Financial Health: The "Survival" Mode

The latest report shows the company is in a very tight spot. They are not yet profitable and are currently in a "growth and survival" phase.

• The Cash Situation: The company has an accumulated deficit of over $60 million. With cash reserves often dipping below $1 million, they have repeatedly warned that they may not have enough capital to sustain operations for the next 12 months without securing additional funding.
• Constant Fundraising: Throughout 2024 and 2025, the company raised money by issuing more shares. This reduces your ownership percentage. To attract investors, they often sold these shares at deep discounts, which put further pressure on the stock price.

3. Major Challenges: The "Reverse Split" Trend

If you follow the stock, you have likely noticed significant price movements. The company uses reverse stock splits to keep their share price above the $1.00 minimum required by the Nasdaq:

• August 2024: 1-for-12 split.
• February 2025: 1-for-5 split.
• January 2026: 1-for-4 split.

These splits combine existing shares into fewer, higher-priced shares. This is a mechanical change that does not improve the underlying business; for 60 Degrees, these moves are necessary to avoid being delisted from the stock exchange.

4. Key Risks

• Dilution: Because the company operates at a loss, it must issue new shares to pay for research and operations. This cycle of issuing more shares constantly shrinks your ownership stake.
• Market Volatility: With a small market value, the stock price can swing wildly based on low trading volume and speculation.
• Dependency: The company relies almost entirely on Arakoda. This drug has struggled to gain a large share of the malaria market. Any regulatory or manufacturing problems could trigger an immediate cash crisis.

5. Future Outlook

The company is racing to reach stability. Management is trying to boost Arakoda sales while advancing new clinical trials. However, the path to profit is narrow. Their survival depends on finding new funding—such as government grants—or a major jump in sales. Neither is guaranteed.

Final Thought for Investors: This is a high-risk investment. The company is currently focused on staying alive, and their financial situation is fragile. Before investing, ask yourself if you are comfortable with the high probability of further dilution and the ongoing uncertainty surrounding their cash flow. If you prefer companies with established profits or stable balance sheets, this may not be the right fit for your portfolio.